The Health Sciences Authority (HSA) would like to inform healthcare professionals about the consumer-level recall of three metformin products which have been detected to contain trace amounts of N-nitrosodimethylamine (NDMA) beyond the internationally acceptable level. HSA has tested all the metformin products in the Singapore market, and found that besides these three products, none of the other 43 metformin products marketed in Singapore contain NDMA above the acceptable level.
Healthcare professionals are advised to stop prescribing or dispensing the three affected metformin products, contact patients who have been prescribed the affected metformin medicines as soon as practicable to return to the clinic for an exchange of unaffected metformin medicine or suitable alternatives and return the remaining stocks of these affected products to the respective companies.
Please refer to the Dear Healthcare Professional Letter (DHCPL) below for more details:
